Promising results for lenvatinib in combination with pembrolizumab or everolimus in 1L advanced renal cell carcinoma

The results of the phase 3 CLEAR-study in 1L treatment of patients with advanced renal cell carcinoma show that lenvatinib in combination with pembrolizumab or everolimus improve progression-free survival and response rate compared to sunitinib, whereas the combination of lenvatinib and pembrolizumab also significantly improves survival.